2018 May 4;14(5):1084-1097. doi: 10.1080/21645515.2018.1434463. It is now 5 years since the UK became the first country to introduce the serogroup C meningococcal polysaccharide–protein conjugate vaccines (MenC) into its routine immunisation schedule.

Meningococcal conjugate vaccine (MCV4) for ages 2 through 55; Meningococcal polysaccharide vaccine (MPSV4) for ages 2 and older including older than 55; Both vaccines can prevent 4 types of meningococcal disease.

eCollection 2017.Delea TE, Weycker D, Atwood M, Neame D, Alvarez FP, Forget E, Langley JM, Chit A.PLoS One.

3,20 Although vaccination with monovalent meningococcal conjugate vaccines against serogroup A and C … Please allow up to 2 business days for review, approval, and posting. By continuing to use our site, or clicking "Continue," you are agreeing to our 2020 American Medical Association.

Public Library of Science Our website uses cookies to enhance your experience. sign up for alerts, and moreto access your subscriptions, sign up for alerts, and moreto access your subscriptions, sign up for alerts, and moreto download free article PDFs, sign up for alerts, customize your interests, and moreto make a comment, download free article PDFs, sign up for alerts and more

2018 Oct;36(10):1201-1222. doi: 10.1007/s40273-018-0679-5.Hum Vaccin Immunother. The information will be posted with your response.Not all submitted comments are published.

They result in a decrease in meningitis and sepsis among populations where they are widely used. Free PMC article The development of a novel multi-serogroup meningococcal conjugate vaccine (NmCV-5) that includes serogroup A is highlighted.

All Rights Reserved 2020;174(9):843-851. doi:10.1001/jamapediatrics.2020.1990What is the association between the quadrivalent meningococcal conjugate vaccination program in adolescents and incidence of meningococcal disease in the United States?The incidence of meningococcal disease was declining prior to introduction of the vaccine.

ICER: incremental cost-effectiveness ratio, QALY: quality adjusted life year. 2019 May 17;4:161-187. doi: 10.1016/j.idm.2019.05.003. This article reviews the global use of MenC with particular reference to the range of immunisation strategies used internationally. doi: 10.1371/journal.pone.0188595.

The PubMed database (1996–2019) was searched for studies relating to MenA outbreaks, vaccine, and immunization strategies; and the Neisseria PubMLST database of 1755 MenA isolates (1915–2019) was reviewed. Clipboard, Search History, and several other advanced features are temporarily unavailable. GlaxoSmithKline had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

2012 May;11(5):523-37. doi: 10.1586/erv.12.32.Expert Rev Vaccines. Although the MenACWY vaccine alone cannot explain the decline of meningococcal disease in the United States, these data suggest that MenACWY vaccination is associated with reduced disease rates in adolescents.© 2020 American Medical Association. 2007 Jul 20;25(29):5433-40. doi: 10.1016/j.vaccine.2007.04.071. Quadrivalent meningococcal (MenACWY) conjugate vaccines .

CFR: case fatality rate.This study was funded by a research grant from GlaxoSmithKline.

COVID-19 is an emerging, rapidly evolving situation.

Polysaccharide vaccines are no longer supplied or recommended for use in Australia. Free PMC article Abstract Vaccination of adolescents has been proposed as a strategy to reduce meningococcal disease incidence among other age groups through herd protection given that adolescents have the highest rates of meningococcal carriage and are considered to be the primary transmitters to other age groups.